SUPPORTING INFORMATION

Total Synthesis of (–)-Sinulariadiolide. A Transannular Approach

Zhanchao Meng and Alois Fürstner*

Max-Planck-Institut für Kohlenforschung, D-45470 Mülheim /Ruhr, Germany email: fuerstner@kofo.mpg.de

Table of Contents

Experimental Details and Characterization Data	S-2
Tables	S-20
Copies of HPLC Traces	S-22
Copies of NMR Spectra of New Compounds	S-23
Comparison of the NMR Spectra of Natural and Synthetic Sinulariadiolide	S-76
References	S-78

Experimental Details and Characterization Data

General. Unless stated otherwise, all reactions were carried out in flame-dried glassware using anhydrous solvents under argon. The solvents were purified by distillation over the following drying agents and were transferred under argon: THF, Et₂O (Mg/anthracene), toluene (Na/K), CH₂Cl₂ (CaH₂), MeOH (Mg, stored over MS 3 Å); DMF, MeCN, Et₃N, pentane and pyridine were dried by an adsorption solvent purification system based on molecular sieves. Thin layer chromatography (TLC): Macherey-Nagel precoated plates (POLYGRAM®SIL/UV254); Flash chromatography: Merck silica gel 60 (40-63 µm) with predistilled or HPLC grade solvents; Celite[®] was dried at 170°C for 48 h under high vacuum (1×10^{-3} mbar) and stored under argon. NMR: Spectra were recorded on Bruker DPX 300, AV 400, AV 500 or AVIII 600 spectrometers in the solvents indicated; chemical shifts (δ) are given in ppm relative to TMS, coupling constants (J) in Hz. The solvent signals were used as references and the chemical shifts converted to the TMS scale (CDCl₃: δ_C = 77.0 ppm; residual CHCl₃ in CDCl₃: δ_H = 7.26 ppm). IR: Spectrum One (Perkin-Elmer) spectrometer, wavenumbers $(\tilde{\nu})$ in cm⁻¹. MS (EI): Finnigan MAT 8200 (70 eV), ESI-MS: ESQ3000 (Bruker), accurate mass determinations: Bruker APEX III FTMS (7 T magnet) or Mat 95 (Finnigan). Optical rotations $([\alpha]_{p}^{20})$ were measured with a Perkin-Elmer Model 343 polarimeter. LC-MS analyses were conducted on a Shimadzu LC/MS 2020 instrument (pumps LC-20AD, autosampler SIL-20AC, column oven CTO-20AC, diode array detector SPD-M20A, controller CBM-20A, ESI detector and software Labsolutions) with an ZORBAX Eclipse Plus C18 1.8 μ m, 3.0 or 4.6 mm ID \times 50 mm (Agilent). A binary gradient of MeCN or MeOH in water or aq. triethylammonium acetate buffer (pH 8) was used at a flow rate of 0.5 (3.0 mm ID) or 0.8 (4.6 mm ID) mL/min. The oven temperature was kept at 35 °C and the detection wave length at 254 nm. Preparative LC was performed with a Shimadzu LC-20A prominence system (pumps LC-20AP, column oven CTO-20AC, diode array detector SPD-M20A, fraction collector FRC-10A, controller CBM-20A and software LC-solution); conditions for each compound are specified below. ee-Determinations were performed by HPLC or GC using the chiral stationary phases under the conditions specified below. Unless stated otherwise, all commercially available compounds (Alfa Aesar, Aldrich, TCI, Strem Chemicals) were used as received.

Methyl (E)-3-methyl-6-oxohex-2-enoate (4). Dimethyl sulfate (3.0 mL, 31.7 mmol) was added

compound as a yellow oil (2.71 g, 58%). ¹H NMR (400 MHz, CDCl₃): $\delta = 9.78$ (t, J = 1.3 Hz, 1H), 5.66 (q, J = 1.3 Hz, 1H), 3.67 (s, 3H), 2.69–2.57 (m, 2H), 2.48–2.44 (m, 2H), 2.16 (d, J = 1.3 Hz, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃): $\delta = 200.5$, 166.8, 157.5, 115.9, 50.9, 41.3, 32.60, 18.8 ppm; IR (film) $\nu = 2951$, 1713, 1435, 1149, 1081 cm⁻¹; MS (EI): m/z (%) 41 (100%), 67 (62%), 95 (44%); HRMS (ESI): m/z calcd. for C₈H₁₂O₃Na [M+Na]⁺: 179.06786, found: 179.06787.


Methyl (R,E)-3-methyl-6-oxo-5-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)hex-2-enoate (5).

Catalyst 8·HBF₄ (979 mg, 3.20 mmol)¹ and CuCl₂ (206 mg, 1.53 Me OTMP Me mmol) were added to a stirred solution of compound 4 (2.0 g, 12.8 mmol) and oven-dried molecular sieves (4 Å, ca. 500 mg) in DMF (12 mL) at -10 °C under air. After stirring at this temperature for 10 min, (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (2.0 g, 12.8 mmol) was added in portions to the resulting green solution. Stirring was continued at -10 °C for 24 h before the mixture was diluted with *tert*-butyl methyl ether (10 mL) and the reaction quenched with sat. aq. NH_4Cl (2 mL) and water (5 mL). The aqueous layer was extracted with tert-butyl methyl ether (3 x 50 mL) and the combined organic layers were dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was purified by flash chromatography on silica (hexanes/tert-butyl methyl ether, 10:1 to 8:1) to afford the title compound as a colorless oil (3.24 g, 81%). $[\alpha]_{p}^{20} = 74.0$ (c = 1.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 9.81$ (d, J = 4.2Hz, 1H), 5.71 (q, J = 1.2, 1.2, 1.2 Hz, 1H), 4.31 (td, J = 6.7, 6.7, 4.2 Hz, 1H), 3.670 (s, 3H), 2.58 (ddd, J = 14.1, 6.5, 1.1 Hz, 1H), 2.48 (ddd, J = 14.1, 6.9, 1.1 Hz, 1H), 2.20 (d, J = 1.3 Hz, 3H),1.60–1.51 (m, 1H), 1.46–1.41 (m, 4H), 1.34–1.25 (m, 1H), 1.170 (s, 3H), 1.12 (s, 9H) ppm; ¹³C NMR (101 MHz, CDCl₃): δ = 202.9, 166.5, 153.8, 118.6, 86.1, 50.9, 41.3, 40.1, 34.3, 33.9, 20.5, 20.3, 19.3, 17.0 ppm; IR (film) v = 2935, 1722, 1650, 1436, 1361, 1224, 1152 cm⁻¹; MS (ESI): m/z: 312 [M+H⁺]; 334 [M+Na⁺]; HRMS (ESI): m/z: calcd. for C₁₇H₃₀NO₄ [M+H⁺]: 312.21693, found: 312.21681.

ee-Determination: Methyl (R,E)-6-hydroxy-3-methyl-5-((2,2,6,6-tetramethylpiperidin-1-yl)-

oxy)hex-2-enoate (S1). Sodium borohydride (64.2 mg, 1.70 mmol) Me Me was added to a solution compound 5 (132 mg, 0.429 mmol) in THF/MeOH (4 mL, 1:1) at 0 °C. The mixture was stirred for 30 min at this temperature before the reaction was quenched with sat. aq. NH_4Cl (10 mL). The aqueous layer was extracted with EtOAc (3 x 30 mL), the combined extracts were washed with brine (50 mL), dried over MgSO₄ and evaporated. The crude material was purified by flash chromatography on silica (hexanes/EtOAc, 3:1) to afford the title compound as a colorless oil (124 mg, 93%, 65.3% ee). [The ee was determined by HPLC analysis: Daicel 150 mm Chiralcel OZ-3R, 4.6 mm i.D. acetonitrile/water = 60/40, v = 1.0mL·min⁻¹, λ = 220 nm, t (major) = 6.21 min, t (minor) = 6.56min.]. $[\alpha]_{D}^{20} = 29.0$ (c = 0.9, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 5.77$ (d, J = 7.2 Hz, 1H), 5.72 (q, J = 1.5, 1.5, 1.0 Hz, 1H), 4.50–4.43 (m, 1H), 3.97 (dd, J = 12.0, 9.5 Hz, 1H), 3.69 (s, 3H), 3.62-3.56 (m, 1H), 2.26-2.20 (m, 1H), 2.24 (s, 3H), 2.09 (ddd, J = 13.6, 4.9, 1.1 Hz, 1H), 1.56-1.52 (m, 1H), 1.49-1.45 (m, 3H), 1.40-1.34 (m, 1H), 1.32 (s, 3H), 1.30 (s, 3H), 1.12 (s, 3H), 1.10 (s, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃): δ = 177.0, 156.3, 117.4, 78.3, 68.1, 61.6, 60.0, 50.9, 42.4, 40.3, 39.9, 34.5, 32.5, 20.6, 20.4, 19.3, 17.1 ppm; IR (film) v = 3305, 2932, 2873, 1719, 1647, 1435, 1224, 1150, 1045 cm⁻¹; MS (ESI): m/z: 314 [M+H⁺]; 336 [M+Na⁺]; HRMS (ESI): m/z: calcd. for C₁₇H₃₂NO₄ [M+H⁺]: 314.23258, found: 314.23274.

Methyl (5R,6S,E)-6-((tert-butyldimethylsilyl)oxy)-3-methyl-5-((2,2,6,6 tetramethylpiperidin-




1-yl)oxy)non-2-en-7-ynoate (6). A solution of 1-propynylmagnesium bromide (0.5 M in THF, 50.0 mL, 25.0 mmol) was added to a solution of compound **5** (6.89 g, 22.1 mmol) in

pentane (100 mL) at -78 °C. The mixture was stirred at this temperature for 30 min and at -20 °C for 1 h. For work up, the mixture was partitioned between sat. aq. NH₄Cl (20 mL) and *tert*-butyl methyl ether (100 mL), the aqueous layer was extracted with *tert*-butyl methyl ether (3 x 150 mL), the combined organic phases were washed with brine (20 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash chromatography on silica (hexanes/*tert*-butyl methyl ether, 10:1 to 4:1) to give the desired alcohol as a colorless oil.

Imidazole (3.01 g, 44.2 mmol) and *tert*-butyldimethylsilyl chloride (5.0 g, 33.2 mmol) were added to a solution of this material in DMF (1.0 mL). After stirring for 10 min, sat. aq. NaHCO₃ (10 mL) was added and the resulting mixture was extracted with *tert*-butyl methyl ether (3 x 30 mL). The combined organic phases were washed with brine (50 mL), dried over MgSO₄, filtered and concentrated. The residue was purified by flash chromatography on silica (hexanes/*tert*-butyl methyl ether, 15:1) to afford the title compound as a colorless oil (6.85 g, 67%). $[a]_D^{20} = 8.7$ (c = 2.0, CHCl₃); ¹H NMR (300 MHz, CDCl₃): $\delta = 5.81$ (s, 1H), 4.83–4.74 (m, 1H), 4.05 (td, J = 6.4, 6.4, 1.6 Hz, 1H), 3.67 (s, 3H), 2.64 (dd, J = 13.0, 6.1 Hz, 1H), 2.47 (dd, J = 13.3, 6.3 Hz, 1H), 2.24 (d, J = 1.2 Hz, 3H), 1.78 (d, J = 2.2 Hz, 3H), 1.60–1.37 (m, 5H), 1.27 (d, J = 13.4 Hz, 1H), 1.20 (s, 3H), 1.09 (s, 9H), 0.90 (s, 9H), 0.14 (s, 3H), 0.07 (s, 3H) ppm; ¹³C NMR (75 MHz, CDCl₃): $\delta = 167.1$, 158.7, 117.7, 84.5, 82.5, 78.9, 63.7, 60.4, 60.0, 50.6, 40.6, 34.3, 34.2, 34.1, 26.0, 20.6, 20.4, 20.4, 19.5, 18.3, 17.2, 3.4, -3.9, -4.8 ppm; IR (film) v = 2929, 2857, 1720, 1648, 1435, 1223, 1148, 1076, 832, 776 cm⁻¹; MS (ESI): m/z: 466 [M+H⁺], 488 [M+Na⁺]; HRMS (ESI): m/z calcd. for C₂₆H₄₈NO₄Si [M+H⁺]: 466.33471, found: 466.33486.

Methyl (3S,5R,6S)-6-((*tert*-butyldimethylsilyl)oxy)-3-hydroxy-3-methyl-5-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)non-7-ynoate (7). A mixture of copper (I) chloride (36.0 mg, 0.364




mmol), sodium *tert*-butoxide (89.8 mg, 0.934 mmol,), and (*S*,*S*)-Me-Duphos (112 mg, 0.366 mmol) in THF (3 mL) was stirred for 30 min at 0 $^{\circ}$ C. Bis(pinacolato)diboron (1.87 g, 7.36 mmol)

was added to the mixture and stirring was continued for 10 min before a solution of compound **6** (2.86 g, 6.14 mmol) in THF (2 mL) was introduced, followed by MeOH (1 mmol, 0.40 mL). After stirring for 2 d, the mixture was adsorbed on silica and purified by flash chromatography to provide the crude borylated ester.

Sodium perborate tetrahydrate (22.7 g, 73.8 mmol) was added to a solution of this crude material in THF/H₂O (10 mL, 1:1) at ambient temperature. The mixture was warmed to 90 °C and stirred at this temperature for 2 d. For work-up, the mixture was diluted with water (20 mL) and the aqueous phase was extracted with *tert*-butyl methyl ether (3 x 50 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered and evaporated. The residue was purified by flash chromatography on silica (hexanes/*tert*-butyl methyl ether, 10:1 to 4:1) to afford the title compound as a colorless oil (2.21 g, 74%). $[\alpha]_{D}^{20} = 1.5$ (c = 1.2, CHCl₃); ¹H NMR

(400 MHz, CDCl₃): $\delta = 6.86$ (s, 1H), 4.43 (dq, J = 4.2, 2.1, 2.1, 2.1 Hz, 1H), 4.33 (ddd, J = 7.4, 4.1, 1.2 Hz, 1H), 3.65 (s, 3H), 2.54 (d, J = 3.3 Hz, 2H), 2.31 (dd, J = 16.1, 7.3 Hz, 1H), 2.20–2.04 (m, 1H), 1.81 (d, J = 2.1 Hz, 3H), 1.61–1.53 (m, 3H), 1.51–1.39 (m, 3H), 1.34 (s, 3H), 1.29 (s, 3H), 1.26 (s, 3H), 1.22 (s, 3H), 1.11 (s, 3H), 0.90 (s, 9H), 0.15 (s, 3H), 0.11 (s, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃): $\delta = 171.8, 82.6, 81.3, 79.2, 68.9, 65.3, 62.2, 60.3, 51.3, 49.6, 40.8, 39.8, 39.7, 33.6, 33.2, 27.6, 27.0, 25.8, 21.3, 21.1, 18.2, 17.0, 3.4, -4.4, -5.0 ppm; IR (film) v = 2929, 2856, 1738, 1472, 1436, 1364, 1251, 1131, 1095, 1064, 835, 777 cm⁻¹; MS (ESI): <math>m/z$: 484 [M+H⁺], 506 [M+Na⁺]; HRMS (ESI): m/z: calcd. for C₂₆H₅₀NO₅Si [M+H⁺]: 484.34528, found: 484.34527.

Methyl 2-((4*S*,6*R*,7*R*)-2-(*tert*-butyl)-4-methyl-7-(prop-1-yn-1-yl)-6-((2,2,6,6 tetramethylpiperidin-1-yl)oxy)-1,3,2-dioxasilepan-4-yl)acetate (S2). A solution of tetrabutylammonium



fluoride (1 M in THF, 0.13 mL, 0.130 mmol) was added to a solution of compound 7 (61.3 mg, 0.127 mmol) in THF (1.0 mL) at 0 °C. The resulting solution was stirred at this temperature for 30 min before the reaction was quenched with sat. aq. NH₄Cl (4 mL). The aqueous layer was extracted with

EtOAc (3 x10 mL), the combined extracts were washed with brine (20 mL), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by flash chromatography on silica (hexanes/EtOAc, 4:1 to 1:1) to give a colorless oil.

2,6-Lutidine (0.15 mL, 1.29 mmol) and di-*tert*-butylsilyl ditriflate (60 μ L, 0.184 mmol) were successively added to a solution of this crude material in CH₂Cl₂ (1.6 mL) at 0 °C. The resulting mixture was stirred at ambient temperature for 5 h. sat.aq. NaHCO₃ (2 mL) was added, the aqueous phase was extracted with CH₂Cl₂ (3 x 5 mL), the combined organic layers were dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash chromatography on silica (hexanes/*tert*-butyl methyl ether, 10:1) to afford the title compound as a colorless oil (10.7 mg, 17%). [α]²⁰_{*D*} = -16.7 (c = 1.3, CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ = 4.33 (dq, *J* = 9.1, 2.1, 2.1, 2.1 Hz, 1H), 4.17 (t, *J* = 9.1, 9.1 Hz, 1H), 3.68 (s, 3H), 2.79 (d, *J* = 15.0 Hz, 1H), 2.75 (d, *J* = 14.7 Hz, 1H), 1.52 (s, 3H), 1.48–1.38 (m, 4H), 1.28 (s, 3H), 1.23 (s, 3H), 1.07 (s, 3H), 1.05 (s, 3H), 1.03 (s, 9H), 0.99 (s, 9H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ = 171.3, 80.9,

80.4, 80.2, 73.6, 68.3, 61.2, 59.4, 51.2, 45.9, 43.2, 40.7, 40.3, 34.5, 34.4, 30.2, 28.1, 27.8, 27.4, 20.8, 20.7, 20.7, 20.6, 17.2, 3.5 ppm; IR (film) v = 2969, 2934, 2858, 1744, 1474, 1436, 1361, 1200, 1129, 1106, 1031, 826, 645 cm⁻¹; MS (ESI): m/z: 509 [M+H⁺], 532 [M+Na⁺]; HRMS (ESI): m/z: calcd. for C₂₈H₅₂NO₅Si [M+H⁺]: 510.36093, found: 510.36114.




Figure S1. Determination of the relative stereochemistry; R = 2,2,6,6 tetramethyl-piperidin-1-yl (TMP)

(1S,4R,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptan-2-one (S3). A solution of (R)-(-)-carvone (10 g, 66.6 mmol) in MeOH (150 mL) was cooled to -20 °C.



(*R*)-(–)-carvone (10 g, 66.6 mmol) in MeOH (150 mL) was cooled to -20 °C. aq. NaOH (32 wt%, 2.5 mL, 20 mmol) and aq. H₂O₂ (35 wt%, 8.5 mL, 175 mmol) were added dropwise to this solution at -20 °C. The resulting mixture was stirred at 0 °C for 4 h before the reaction was quenched by careful addition


of sat. aq. Na₂S₂O₃ (100 mL). Diethyl ether and water were added and the phases were separated. The aqueous layer was extracted with diethyl ether (3 x 200 mL), and the combined organic layers were washed with brine and dried with MgSO₄. After filtration, the solvent was removed under vacuum to afford the title compound as a colorless oil, which was directly used in the next step (11.2 g, quant.). $[\alpha]_{D}^{20} = 85.6$ (c = 1.7, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 4.78$ (t, J = 1.5, 1.5 Hz, 1H), 4.71 (s, 1H), 3.45–3.42 (m, 1H), 2.72 (tt, J = 11.1, 11.1, 4.5, 4.5 Hz, 1H), 2.58 (ddd, J = 17.7, 4.7, 1.4 Hz, 1H), 2.41–2.33 (m, 1H), 2.02 (dd, J = 17.6, 11.6 Hz, 1H), 1.89 (ddd, J = 14.8, 11.1, 1.3 Hz, 1H), 1.71 (s, 3H), 1.41 (s, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃): $\delta = 205.5, 146.3, 110.5, 61.3, 58.8, 41.8, 35.0, 28.7, 20.6, 15.3 ppm; IR (film) v = 2935, 1646, 1439, 1377, 1118, 890, 814 cm⁻¹; MS (EI): <math>m/z$ (%): 105 (100), 123 (46); HRMS (ESI): m/z: calcd. for C₁₀H₁₄NNa [*M*+Na⁺]: 189.08860, found: 189.08868.

(S)-3-(Prop-1-en-2-yl)hept-5-ynal (10). Tosylhydrazide (2.46 g, 13.2 mmol) was added in portions to a stirred solution of compound S3 (1.83 g, 12.0 mmol) in HOAc/CH₂Cl₂ (1:1, 34 mL) at 0 °C. The mixture was allowed to slowly warm to 10 °C. After stirring for 2 h, crushed ice (20 g) was added and the phases were separated. The aqueous Мe layer was extracted with CH_2Cl_2 (5 × 200 mL), and the combined organic phases were neutralized with ice-cold sat. aq. NaHCO3 and dried over Na2SO4. The solvent Ŵе was removed under vacuum and the residue purified by flash chromatography on silica (pentane/tert-butyl methyl ether, 10:1) to afford the title compound as a colorless oil (932 mg, 52%). $[\alpha]_{D}^{20} = -18.1$ (c = 0.52, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 9.72$ (dd, J = 2.6, 1.8Hz, 1H), 4.83 (p, J = 1.5, 1.5, 1.5, 1.5, Hz, 1H), 4.79 (dt, J = 1.6, 0.9, 0.9 Hz, 1H), 2.85–2.75 (m, 1H), 2.69 (ddd, J = 16.6, 6.1, 1.8 Hz, 1H), 2.52 (ddd, J = 16.5, 8.3, 2.5 Hz, 1H), 2.38–2.29 (m, 1.5, 0.8 Hz, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃): $\delta = 201.9$, 145.6, 112.0, 78.0, 76.5, 46.3, 40.6, 23.7, 20.2, 3.4 ppm; IR (film) v = 2920, 1722, 1646, 1436, 1260, 1016, 895 cm⁻¹; MS (EI): m/z (%): 41 (100), 91 (94), 107 (47); HRMS (ESI): m/z: calcd. for C₁₀H₁₅O [M+H⁺]: 151.11174, found: 151.11185.

(S)-3-(Prop-1-en-2-yl)hept-5-ynoic acid (11). Sodium chlorite (8.30 g, 91.8 mmol) was added in portions to a stirred solution of compound 10 (6.92 g, 46.1 mmol), 2-methyl-2butene (25 ml, 235 mmol) and sodium dihydrogen phosphate (24.7 g, 225 mmol) in *t*BuOH/H₂O (180 mL, 2:1) at 0 °C. The mixture was stirred at this temperature for 10 min before the reaction was quenched with sat. aq. Na₂S₂O₃ (24 mL). After extraction with EtOAc (3 × 200 mL), the combined organic phases were washed with brine, dried over Na₂SO₄ and filtered. The solvent was evaporated under

vacuum and the residue was purified by flash chromatography (hexanes/*tert*-butyl methyl ether, 15:1 to 2:1) to afford the title compound as a colorless oil (7.19 g, 94%). $[\alpha]_D^{20} = -19.2$ (c = 2.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 4.82-4.81$ (m, 1H), 4.79 (s, 1H), 2.73–2.68 (m, 1H), 2.68–2.64 (m, 1H), 2.50–2.42 (m, 1H), 2.32 (ddq, J = 16.7, 5.2, 2.5, 2.5, 2.5, Hz, 1H), 2.21 (ddq, J = 16.8, 7.5, 2.5, 2.5, 2.5, 2.5, Hz, 1H), 1.75 (dd, J = 2.5, 2.5, Hz, 3H), 1.72 (s, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃): $\delta = 179.2, 145.6, 111.7, 77.6, 76.4, 42.0, 37.5, 23.5, 20.2, 3.4 ppm; IR (film) v = 2920, 1648, 1432, 1289, 1163, 894 cm⁻¹; MS (EI): <math>m/z$ (%): 41 (87), 91 (100), 121 (41); HRMS (ESI): m/z: calcd. for C₁₀H₁₃O₂[M-H⁺]: 165.09211, found: 165.09213.

Methyl (35,5*R*,6*S*)-6-((*tert*-butyldimethylsilyl)oxy)-3-methyl-3-(((*S*)-3-oxo-5-(prop-1-en-2-yl) non-7-ynoyl)oxy)-5-((2,2,6,6-tetramethylpiperidin-1-yl)oxy) non-7-ynoate (15). Compound 12 (1.29 g, 6.26 mmol)² was added to a solution of 4-dimethylaminopyridine (127 mg, 1.04 mmol), triethylamine (1.75 mL, 12.6 mmol) and dicyclohexylcarbodiimide (2.15 g, 10.4 mmol) in CH₂Cl₂ (10 mL) at ambient temperature. After 5 min, a solution of acid 11 (1.04 g, 6.26 mmol) in THF (10 mL) was added and stirring continued for 20 h. The mixture was concentrated and the residue triturated with diethyl ether (20 mL) and H₂O (20 mL). The biphasic suspension was filtered and the filter cake was carefully washed with diethyl ether (3 x 30 mL) and H₂O (5 x 50 mL), the combined aqueous phases were cooled to 0 °C, acidified to pH 2-3 with solid citric acid and extracted with CHCl₃ (5 x 50 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated (T ≤ 30°C).




The crude compound **13** (1.01 g, 2.09 mmol) thus formed was added to a solution of **7** (1.01 g, 2.09 mmol) in toluene (6 mL) and the resulting mixture was stirred at 60 °C for 1.5 h. sat. aq. NaHCO₃ (20 mL) was added, the aqueous phase was extracted with *tert*-butyl methyl ether (3 x 50 mL), the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and

evaporated. The residue was purified by flash chromatography on silica (hexanes/tert-butyl methyl ether, 10:1) to afford the title compound as a yellow oil (1.39 g, quant.). $[a]_D^{20} = +18.9$ (c = 1.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 12.1$ (s, 0.3H, minor), 5.21 (dt, J = 3.0, 2.0, 2.0 Hz, 1H), 4.93 (s, 0.3H, minor), 4.81 (tt, J = 3.0, 3.0, 1.5, 1.5 Hz, 0.3H), 4.80 (tt, J = 1.7, 1.7, 0.9, 0.9 Hz, 0.7H), 4.77–4.76 (m, 1H), 4.15–4.11 (m, 1H), 3.66 (s, 2H), 3.65 (s, 1H), 3.41 (d, J = 15.3 Hz, 0.7H), 3.34 (d, J = 15.3 Hz, 0.7H), 3.22 (dd, J = 25.7, 15.0 Hz, 1H), 3.00 (dd, J = 19.6, 14.9 Hz, 1H), 2.83 (dd, J = 14.8, 5.0 Hz, 0.6H), 2.79– 2.70 (m, 1.4H), 2.44–2.20 (m, 5H), 1.80 (dd, J = 3.8, 2.3 Hz, 2H), 1.79 (q, J = 2.6, 2.6, 2.6 Hz, 1H), 1.77–1.75 (m, 3H), 1.72–1.70 (m, 6H), 1.50–1.38 (m, 5H), 1.30–1.25 (m, 1H), 1.15 (t, J = 6.1, 6.1 Hz, 9H), 1.05 (s, 3H), 0.88 (s, 9H), 0.16 (s, 3H), 0.08–0.07 (m, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃): $\delta = 201.7, 176.3, 172.1, 170.7, 170.5, 166.2, 146.2, 145.6, 112.0, 111.4, 91.8, 83.1, 83.0, 82.7, 82.2, 81.7, 79.6, 77.5, 76.7, 62.7, 62.6, 60.3, 59.8, 51.4, 51.4, 50.8, 45.7, 43.7, 43.1, 42.8, 40.8, 40.5, 38.3, 38.3, 38.2, 34.8, 34.3, 26.1, 25.6, 25.2, 23.5, 23.2, 20.8, 20.6, 19.9, 18.4, 17.2, 17.2, 3.5, 3.5, -3.5, -4.3$

ppm; IR (film) v = 2929, 2856, 1741, 1646, 1249, 1204, 1164,1134, 1084, 1063, 894 cm⁻¹; MS (ESI): m/z: 674 [M+H⁺], 696 [M+Na⁺]; HRMS (ESI): m/z: calcd. for C₃₈H₆₄NO₇ [M+H⁺]: 674.44466, found: 674.44461.

Methyl (3S,5R,6S)-6-hydroxy-3-methyl-3-(((S)-3-oxo-5-(prop-1-en-2-yl)non-7-ynoyl)oxy)-5-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)non-7-ynoate (16). Triethylamine (0.47 mL, 3.37)




mmol), acetic anhydride (0.32 mL, 3.39 mmol) and 4dimethylaminopyridine (27.6 mg, 0.226 mmol) were added to a stirred solution of compound **15** (760 mg, 1.13 mmol) in CH₂Cl₂ (5.6 mL) at -40 °C. After stirring at this temperature for 2 h, the reaction was quenched with sat. aq. NaHCO₃ (5 mL) and the aqueous phase was extracted with EtOAc (3 x 20 mL). The

combined organic layers were washed with brine, dried over Na_2SO_4 filtered and evaporated. The residue was passed through a pad of silica, eluting with hexanes/*tert*-butyl methyl ether (10:1) to provide the corresponding enol acetate as a colorless oil, which was used in the next step without further characterization.

aq. HF (1.5 mL) was added to a solution of this compound in THF (15 mL) at 0 °C. After 10 min, stirring was continued at ambient temperature for 2 h. The mixture was then poured into sat. aq. NaHCO₃ (100 mL) at 0 °C and the aqueous phase was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine, dried over MgSO₄, filtered and evaporated. The residue was purified by flash chromatography on silica (hexanes/*tert*-butyl methyl ether, 10:1 to 4:1) to afford the title compound as a colorless oil (498 mg, 73%). $[a]_{D}^{20} = 17.8$ (c = 2.6, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 5.72$ (s, 1H), 5.65 (s, 1H), 4.80–4.77 (m, 1H), 4.75–4.71 (m, 1H), 4.67 (s, 1H), 4.49 (dt, J = 7.0, 3.3, 3.3 Hz, 1H), 3.65 (s, 3H), 3.20 (d, J = 15.1 Hz, 1H), 3.10 (dd, J = 14.4, 8.9 Hz, 1H), 2.98–2.87 (m, 2H), 2.51–2.43 (m, 1H), 2.39 (dd, J = 15.4, 7.3 Hz, 1H), 2.26–2.19 (m, 2H), 2.14 (s, 3H), 2.06 (dd, J = 15.4, 3.5 Hz, 1H), 1.81 (d, J = 2.3 Hz, 3H), 1.74 (t, J = 2.5, 2.5 Hz, 3H), 1.68 (s, 3H), 1.66 (s, 3H), 1.52–1.41 (m, 5H), 1.37 (s, 3H), 1.29 (s, 3H), 1.17 (s, 3H), 1.08 (s, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃): $\delta = 170.4, 167.8, 165.0, 164.6, 145.6, 112.2, 111.9, 82.7, 81.0, 78.4, 78.0, 77.1, 77.0, 67.3, 61.3, 60.7, 51.4, 44.4, 42.7, 40.9, 40.4, 39.6, 34.7, 33.9, 33.4, 25.3, 23.4, 21.1, 21.0, 20.7, 19.1, 17.0, 3.6, 3.4 cm⁻¹; IR (film) v = 2923, 2873, 1764, 1717, 1655, 1473, 1437, 1365, 1198, 1169, 1094, 1021, 896, 753$

cm⁻¹; MS (ESI): m/z: 602 [M+H⁺], 624 [M+Na⁺]; HRMS (ESI): m/z: calcd. for C₃₄H₅₂O₈N [M+H⁺]: 602.36874, found: 602.36895.

Methyl 2-((2*S*,4*R*,5*S*,9*S*,*Z*)-11-acetoxy-4,5-dihydroxy-2-methyl-13-oxo-9-(prop-1-en-2-yl) oxacyclotridec-11-en-6-yn-2-yl)acetate (17). A solution of silanol 24 (51.0 mg, 0.0648 mmol)




in toluene (1 mL) was added to complex **23** (37.7 mg, 0.0648 mmol) at ambinent temperature.^[3] After stirring for 10 min, the resulting catalyst solution was added to a solution of diyne **16** (130 mg, 0.216 mmol) in refluxing toluene (97 mL). After 15 min, the mixture was allowed to cool to ambient

temperature, filtered through a pad of Celite and the filtrate was concentrated. The crude material was passed through a pad of silica, eluting with hexanes/EtOAc (4:1).

Zinc dust (565 mg, 8.64 mmol) was added to a solution of this compound in HOAc/THF/H₂O (0.75 mL, 3:1:1). The suspension was vigorously stirred for 2 h at room temperature before all insoluble materials were filtered off through a pad of Celite. The filtrate was diluted with sat. aq. NaHCO₃ (10 mL), the aqueous phase was extracted with EtOAc (3 x 20 mL), the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash chromatography on silica (hexanes/EtOAc, 4:1 to 1:1) to afford the title compound as a colorless oil (67.4 mg, 76%). $[\alpha]_{D}^{20} = 8.5$ (c = 0.4, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 5.54$ (d, J = 0.6 Hz, 1H), 4.75 (t, J = 1.5, 1.5 Hz, 1H), 4.69 (s, 1H), 4.51 (s, 1H), 4.07 (ddd, J = 8.6, 5.9, 2.6 Hz, 1H), 3.74 (d, J = 5.6 Hz, 1H), 3.68–3.64 (m, 1H), 3.64 (s, 3H), 3.34 (dd, J = 14.5, 4.9 Hz, 1H), 2.99 (d, J = 14.6 Hz, 1H), 2.64 (dd, J = 14.4, 11.0 Hz, 1H), 2.57 (d, J = 16.4 Hz, 1H), 2.48 (d, J = 3.4 Hz, 1H), 2.42 (ddt, J = 11.0, 9.1, 4.5, 4.5 Hz, 1H), 2.3016.2, 8.5 Hz, 1H), 1.65 (s, 3H), 1.63 (s, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃): $\delta = 172.7, 167.9,$ 164.9, 163.0, 144.7, 114.0, 112.7, 85.4, 83.1, 81.3, 71.5, 67.1, 52.1, 44.5, 42.3, 39.8, 33.4, 25.6, 23.9, 21.0, 19.9 ppm; IR (film) v = 3447, 3080, 2923, 2853, 1739, 1698, 1437, 1200, 1078, 1016, 889 cm⁻¹; MS (ESI): m/z: 431 [M+Na⁺]; HRMS (ESI): m/z: calcd. for C₂₁H₂₈O₈Na [M+Na⁺]: 431.16764, found: 431.16747.


Methyl 2-((2S,4R,5R,6Z,9S,11Z)-11-acetoxy-4,5-dihydroxy-2-methyl-13-oxo-9-(prop-1-en-2-



yl)-6-(tributylstannyl)oxacyclotrideca-6,11-dien-2-yl)acetate
(18). A solution of tributyltin hydride (53 μL, 0.197 mmol) in
CH₂Cl₂ (0.7 mL) was added dropwise over 20 min to a stirred orange solution of [Cp*RuCl]₄ (2.0 mg, 1.8 μmol) and

compound **17** (67.4 mg, 0.165 mmol) in CH₂Cl₂ (0.14 mL) under Ar at 23°C. Once the addition was complete, all volatile materials were evaporated under argon. The crude material was purified by flash chromatography on silica (hexanes/*tert*-butyl methyl ether, 4:1 to 2:1) to afford the title compound as a yellow oil (76.2 mg, 66%). $[\alpha]_D^{20} = 24.2$ (c = 0.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 6.22$ (ddd, J = 10.0, 5.1, 1.8 Hz, 1H), 5.54 (d, J = 0.6 Hz, 1H), 4.82 (t, J = 1.5, 1.5 Hz, 1H), 4.66 (s, 1H), 4.50 (s, 1H), 3.91 (ddd, J = 8.0, 4.7, 3.1 Hz, 1H), 3.71 (s, 3H), 3.66 (s, 1H), 3.64 (s, 1H), 3.04 (d, J = 6.2 Hz, 1H), 3.00 (d, J = 5.5 Hz, 1H), 2.76 (dd, J = 14.6, 10.9 Hz, 1H), 2.36 (d, J = 2.4 Hz, 1H), 2.24 (ddd, J = 20.4, 8.9, 4.4 Hz, 4H), 2.10 (s, 3H), 1.92–1.80 (m, 1H), 1.73 (s, 3H), 1.66 (s, 3H), 1.32 (dq, J = 13.7, 7.2, 7.2, 6.6 Hz, 12H), 1.00–0.95 (m, 6H), 0.88 (t, J = 7.3, 7.3 Hz, 9H) ppm; ¹³C NMR (101 MHz, CDCl₃): $\delta = 172.9, 167.8, 165.0, 163.6, 148.8, 145.7, 137.9, 113.8, 111.9, 83.3, 80.6, 73.9, 52.1, 46.3, 41.2, 39.7, 35.3, 32.8, 29.2, 29.2, 27.8, 27.5, 26.8, 25.7, 21.0, 20.7, 17.5, 13.7, 13.6, 12.2 ppm; ¹¹⁹Sn NMR (186 MHz, CDCl₃): <math>\delta = -58.3$ ppm; IR (film) v = 3503, 2955, 2923, 2853, 1742, 1700, 1374, 1190, 1069, 1015, 892 cm⁻¹; MS (ESI): m/z: 723 [M+Na⁺]; HRMS (ESI): m/z: calcd. for C₃₃H₅₆O₈SnNa [M+Na⁺]: 723.28887, found: 723.28927.

Methyl (2*S*,4*R*,5*S*,6*Z*,9*S*,11*Z*)-11-acetoxy-4,5-dihydroxy-2-(2-methoxy-2-oxoethyl)-2-methyl-13-oxo-9-(prop-1-en-2-yl)oxacyclotrideca-6,11-diene-6-carboxylate (19). *p*-Benzoquinone




(10.5 mg, 0.0971 mmol), Ph₃As (7.9 mg, 0.0258 mmol) and Pd(OAc)₂ (2.9 mg, 0.0129 mmol) were added to a solution of compound **18** (45.3 mg, 0.0648 mmol) and trifluoroacetic acid (2 μ L, 0.0259 mmol) in MeOH (1.6 mL). The Schlenk flask was flushed for 5 min with CO before the mixture was stirred

under CO atmosphere (balloon) at room temperature for 2 h. The mixture was diluted with EtOAc and filtered through a pad of Celite. sat.aq. NaHCO₃ (5 mL) was added to the filtrate and the aqueous phase was extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and evaporated. The residue was purified by flash

chromatography (hexanes/ EtOAc, 2:1 to 1:2) to afford the title compound as a white solid (17.3 mg, 57%). $[\alpha]_{D}^{20} = 4.0$ (c = 0.2, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 6.34$ (t, J = 8.1, 8.1 Hz, 1H), 5.52 (s, 1H), 4.88–4.77 (m, 1H), 4.74 (d, J = 4.2 Hz, 1H), 4.71 (s, 1H), 3.96 (t, J = 6.6, 6.6 Hz, 1H), 3.79 (s, 3H), 3.70 (dd, J = 16.0, 1.4 Hz, 1H), 3.69 (s, 3H), 3.00–2.91 (m, 3H), 2.84 (d, J = 4.7 Hz, 1H), 2.53 (dd, J = 14.5, 11.0 Hz, 1H), 2.41–2.28 (m, 3H), 2.08 (s, 3H), 1.91 (dd, J = 16.4, 7.9 Hz, 1H), 1.75 (s, 3H), 1.71 (s, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃): $\delta = 172.2, 167.9, 167.3, 164.8, 163.0, 146.0, 140.4, 132.8, 114.0, 111.9, 83.2, 75.7, 72.1, 51.9, 51.8, 45.0, 40.7, 39.6, 32.6, 32.3, 25.5, 21.0, 20.0$ ppm; IR (film) v = 3481, 2952, 1697, 1648, 1436, 1355, 1128, 1062, 889,804 cm⁻¹; MS (ESI): m/z: 469 [M+H⁺], 491 [M+Na⁺]; HRMS (ESI): m/z: calcd. for C₂₃H₃₂O₁₀Na [M+Na⁺]: 491.18877, found: 491.18832.


Methyl 2-((1*R*,3*S*,6*Z*,9*S*,11*Z*,15*S*)-7-acetoxy-15-hydroxy-3-methyl-5,13-dioxo-9-(prop-1-en-2-yl)-4,14-dioxabicyclo[10.2.1]pentadeca-6,11-dien-3-yl)acetate (20). A solution of CF₃COOH



 $(0.4 \ \mu\text{L}, 5.1 \ \mu\text{mol})$ in CH₂Cl₂ $(0.1 \ \text{mL})$ was added to a solution of **19** (2.0 mg, 4.3 μ mol) in CH₂Cl₂ (0.1 mL) at ambient temperature. The mixture was stirred at this temperature for 2 h, the solvent was removed under argon and the residue was purified by flash chromatography (hexanes/EtOAc, 4:1 to 2:1)

to afford the title compound as a colorless oil (1.7 mg, 91%). $[\alpha]_D^{20} = 5.0$ (c = 0.12, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 6.31$ (t, J = 8.3, 8.3 Hz, 1H), 5.62 (s, 1H), 5.07 (s, 1H), 4.85–4.79 (m, 1H), 4.70 (s, 1H), 4.45 (d, J = 10.2 Hz, 1H), 3.83 (s, 3H), 3.27 (d, J = 17.5 Hz, 1H), 3.15 (d, J = 17.4 Hz, 1H), 2.92–2.80 (m, 2H), 2.61–2.47 (m, 2H), 2.43–2.32 (m, 2H), 2.10 (s, 3H), 1.81 (dd, J = 15.4, 10.3 Hz, 1H), 1.76 (s, 3H), 1.70 (s, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃): $\delta = 170.2$, 167.7, 166.7, 164.6, 162.9, 145.8, 140.3, 133.1, 113.4, 112.2, 80.9, 79.2, 70.6, 52.2, 45.8, 43.4, 37.7, 33.5, 33.2, 27.0, 21.0, 19.7 ppm; IR (film) v = 2924, 1707, 1437, 1195, 1105, 1026, 459 cm⁻¹; MS (ESI): m/z: 459 [M+Na⁺]; HRMS (ESI): m/z: calcd. for C₂₂H₂₈O₉Na [M+Na⁺]: 459.16290, found: 459.16255.


Methyl (1R,2R,4S)-2-((S)-1-((4S,5S)-5-((R)-2-hydroxy-4-methoxy-2-methyl-4-oxobutyl)-2,2dimethyl-1,3-dioxolan-4-yl)-2-methoxy-2-oxoethyl)-6-oxo-4-(prop-1-en-2-yl)cyclohexane-1carboxylate (30): 2,2-Dimethoxypropan (40 μ L, 0.325 mmol) and PPTS (3.1 mg, 12.3 μ mol) were added to a stirred solution of 19 (2.0 mg, 4.3 μ mol) in DMF (40 μ L) at ambient temperature and the resulting mixture was stirred for 12 h. The reaction was quenched with sat. $aq.NaHCO_3$ (1.0 mL), the aqueous layer was extracted with ether (3 x 5 mL), dried over Na_2SO_4 and



evaporated. The crude material was purified by flash chromatography (hexanes/ EtOAc, 6:1 to 2:1) to give product **29** which was immediately used in the next step. This compound was dissolved in MeOH (0.8 mL). Cs_2CO_3 (5.5 mg, 16.9 μ mol) was added at 0 °C and the resulting

mixture was stirred for 20 min before the reaction was quenched with aq. NH₄Cl (0.5 mL). The aqueous phase was extracted with EtOAc (3 x 5 mL), the combined extracts were dried over MgSO₄, the solvent was evaporated and the residue purified by flash chromatography (hexanes/EtOAc, 4:1 to 1:1) to afford the title compound **30** as a colorless oil (0.9 mg, \approx 42%; *the samples invariably contained ca.* 5-10% of an unidentified impurity, which could not be removed by flash chromatography) [a]²⁰_D = 20 (c = 0.04, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ = 4.85–4.81 (m, 1H), 4.76 (s, 1H), 4.53 (ddd, *J* = 10.3, 5.6, 3.1 Hz, 1H), 4.25 (dd, *J* = 9.9, 5.6 Hz, 1H), 3.81 (s, 3H), 3.75 (s, 3H), 3.67 (s, 3H), 3.45 (d, *J* = 11.4 Hz, 1H), 2.77 (dd, *J* = 9.9, 2.1 Hz, 1H), 2.67 (d, *J* = 15.2 Hz, 1H), 2.56–2.42 (m, 3H), 2.38 (dt, *J* = 11.9, 2.9, 2.9 Hz, 1H), 2.25 (td, *J* = 13.3, 13.3, 0.9 Hz, 1H), 2.08 (d, *J* = 13.9 Hz, 1H), 1.88–1.79 (m, 2H), 1.76 (s, 3H), 1.68–1.57 (m, 1H), 1.42 (s, 3H), 1.38 (s, 3H), 1.28 (s, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ = 204.9, 172.4, 171.6, 170.7, 146.2, 110.6, 108.5, 76.1, 74.2, 70.8, 59.4, 52.4, 51.8, 51.6, 50.5, 46.0, 45.8, 43.1, 39.5, 38.1, 35.9, 27.9, 27.5, 25.7, 20.4. ppm; IR (film) v = 2924, 1735, 1437, 1217, 756 cm⁻¹; MS (ESI): *m/z*: 521 [*M*+Na⁺]; HRMS (ESI): *m/z*: calcd. for C₂₅H₃₈O₁₀Na [*M*+Na⁺]: 521.23563, found: 521.23572.

Methyl (3*S*,5*S*,6*S*,7*S*,7*aS*,9*S*,11*aS*)-3-(2-methoxy-2-oxoethyl)-3-methyl-1,11-dioxo-9-(prop-1en-2-yl)-5,6-bis((trimethylsilyl)oxy)dodecahydrobenzo[c]oxonine-7-carboxylate (32a).



Imidazole (72.0 mg, 1.06 mmol) and trimethylsilyl chloride (0.13 mL, 1.02 mmol) were added to a solution of compound **19** (8.0 mg, 0.0171 mmol) in DMF (0.2 mL) at ambient temperature. After stirring for 4 h, the reaction was quenched

with sat.aq. NaHCO₃ (2 mL) and the aqueous layer was extracted with EtOAc (3 x 3 mL). the combined organic phases were washed with birne, dried over Na_2SO_4 , filtered and evaporated.

The residue was dried in vacuum for 30 min before it was passed through a pad of silica, eluting with hexanes/EtOAc (8:1) to provide the hydrolysis-prone compound **31a** as a colorless oil. Characteristic data: ¹H NMR (400 MHz, CDCl₃): $\delta = 6.20$ (dd, J = 11.1, 5.6 Hz, 1H), 4.82 (s, 1H), 4.79–4.76 (m, 1H), 4.68 (s, 1H), 3.96 (d, J = 7.5 Hz, 1H), 3.81 (s, 3H), 3.64 (s, 3H), 1.77 (s, 3H), 1.61 (s, 3H) ppm.

A solution of Barton's base **33** (8.8 mg, 0.0514 mmol) in CH₃CN (0.2 mL) was added to a solution of **31a** in CH₃CN (0.1 mL) at 0 °C. After stirring for 1 min, the mixture was adsorbed on silica and the product purified by flash chromatography (hexanes/EtOAc, 8:1) to afford the title compound as a colorless oil (5.5 mg, 56%). $[\alpha]_D^{20} = -38.3$ (c = 0.12, CHCl₃); ¹H NMR (600 MHz, CDCl₃): $\delta = 4.79$ (t, J = 1.5 Hz, 1H), 4.71 (q, J = 1.1 Hz, 1H), 4.28 (dd, J = 10.5, 1.4 Hz, 1H), 4.12 (dt, J = 8.0, 1.3 Hz, 1H), 3.74 (d, J = 12.2 Hz, 1H), 3.71 (s, 3H), 3.67 (s, 3H), 3.39 (d, J = 15.0 Hz, 1H), 3.03 (tt, J = 12.6, 3.9 Hz, 1H), 2.94 (dd, J = 10.5, 4.5 Hz, 1H), 2.50 (ddd, J = 14.1, 3.5, 2.2 Hz, 1H), 2.44 (d, J = 15.1 Hz, 1H), 1.90 (dt, J = 13.4, 3.0 Hz, 1H), 1.73–1.72 (m, 3H), 1.57 (s, 3H), 1.17 (q, J = 12.8 Hz, 1H), 0.16 (s, 9H), 0.04 (s, 9H) ppm; ¹³C NMR (151 MHz, CDCl₃): $\delta = 205.0$, 173.6, 171.1, 170.8, 146.6, 110.2, 80.7, 78.3, 76.0, 60.5, 55.9, 51.6, 51.1, 46.4, 45.8, 43.1, 42.3, 39.2, 35.2, 27.6, 20.4, 0.22, -0.10 ppm; IR (film) v = 2954, 2855, 1740, 1252, 1160, 1057, 842 cm⁻¹; MS (ESI): m/z: 588 [M+NH₄⁺], 593 [M+Na⁺]; HRMS (ESI): m/z calcd. for C₂₇H₄₆O₉Si₂Na [M+Na⁺]: 593.25726, found: 593.25710.






Figure S2. Relevant NOE contacts at the ring junction; R = TMS

Scheme S1. Influence of the Base on the Stereochemical Outcome of the Transannular Michael Addition^{*a*}



^{*a*} Characteristic region of the ¹H NMR spectrum (CDCl₃) of the crude reaction mixture; top: Cs₂CO₃, CH₂Cl₂, MeOH/H₂O; bottom: 2-*tert*-butyl-1,1,3,3,-tetramethylguanidine (Barton's base, **33**), MeCN

Methyl (*3aS*,*5S*,*8Z*,*11S*,*13Z*,*14aS*)-9-acetoxy-5-(2-methoxy-2-oxoethyl)-5-methyl-2,7-dioxo-11-(prop-1-en-2-yl)-3a,4,5,7,10,11,12,14a-octahydro-[1,3]dioxolo[4,5-d][1]oxacyclotridecine-




14-carboxylate (25). Triphosgene (54.5 mg, 0.184 mmol) was added in small portions to a solution of compound **19** (17.2 mg, 0.036 mmol) in CH₂Cl₂/pyridine (7:1, 1.14 mL) at 0 °C and the resulting mixture was stirred at this temperature for 3 h. The reaction was quenched at 0 °C with sat. aq. NaHCO₃ (4 mL)

and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic phases were washed with brine, dried over MgSO₄, filtered and evaporated. The residue was purified by flash chromatography on silica (hexane/EtOAc, 3:2) to afford the title compound as a colorless oil (17.6 mg, 97%). [α]²⁰_{*p*} = 9.0 (c = 0.4, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ = 6.51 (t, *J* = 6.4, 6.4 Hz, 1H), 5.64 (s, 1H), 5.37 (d, *J* = 8.2 Hz, 1H), 5.25 (td, *J* = 8.7, 8.5, 3.2 Hz, 1H), 4.92 (s,

1H), 4.79 (q, J = 1.1, 1.1, 1.1 Hz, 1H), 3.79 (s, 3H), 3.71 (s, 3H), 3.39–3.35 (s, 1H), 3.06 (d, J = 15.1 Hz, 1H), 2.99 (d, J = 15.1 Hz, 1H), 2.95–2.88 (m, 2H), 2.58 (dd, J = 16.5, 9.1 Hz, 2H), 2.53 (dt, J = 9.0, 4.7, 4.7 Hz, 1H), 2.37 (dd, J = 16.5, 2.5 Hz, 1H), 2.14 (s, 3H), 1.80 (s, 3H), 1.59 (s, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃): $\delta = 169.7$, 167.9, 165.4, 165.1, 163.9, 154.0, 124.8, 113.2, 111.3, 80.4, 77.4, 53.4, 52.0, 51.9, 41.8, 32.0, 29.7, 27.8, 26.8, 22.1, 21.1, 17.5, 13.6, 1.0 ppm; IR (film) $\nu = 2948$, 1800, 1677, 1594, 1366, 1257, 1165, 1019, 835, 754 cm⁻¹; MS (ESI): m/z: 512 [M+NH₄⁺], 517 [M+Na⁺]; HRMS (ESI): m/z: calcd. for C₂₄H₃₀O₁₁Na [M+Na⁺]: 517.16803, found: 517.16811.


Methyl 2-((*3S*,5*R*,8*aS*,10*S*,12*aR*,*Z*)-3-methyl-1,7,12-trioxo-10-(prop-1-en-2-yl)-4,5,8a,9,10,11,12,12a-octahydro-1*H*,3*H*,7*H*-5,8-(metheno)benzo[g][1,5]dioxecin-3-yl)acetate



(27). Caesium carbonate (19.3 mg, 0.0592 mmol) was added to a solution of compound 25 (5.6 mg, 0.0113 mmol) in $CH_2Cl_2/CCl_3CH_2OH/H_2O$ (0.65 mL, 3:1:1) at 0 °C. The mixture was stirred for 10 min at this temperature and for 3 h at ambient temperature before the reaction was quenched with

sat. aq. NH₄Cl (5 mL). The aqueous phase was extracted with EtOAc (3 x 4 mL), the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash chromatography on silica (hexanes/EtOAc, 1:1) to afford the title compound as a colorless oil (3.7 mg, 87%). $[\alpha]_{D}^{20} = -4.5$ (c = 0.3, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 6.98$ (d, J = 1.5 Hz, 1H), 5.27 (d, J = 8.5 Hz, 1H), 4.99 (s, 1H), 4.79 (s, 1H), 3.65 (s, 3H), 3.43 (d, J = 12.1 Hz, 1H), 3.36 (d, J = 15.1 Hz, 1H), 3.22 (td, J = 12.2, 12.1, 3.4 Hz, 1H), 3.07 (d, J = 15.1 Hz, 1H), 2.88 (s, 1H), 2.81 (ddd, J = 13.9, 12.5, 5.6 Hz, 1H), 2.70 (ddd, J = 15.4, 3.3, 1.7 Hz, 1H), 2.57–2.53 (m, 1H), 2.53–2.49 (m, 1H), 2.39 (d, J = 15.2 Hz, 1H), 2.17 (dtd, J = 14.0, 3.5, 3.3, 1.8 Hz, 1H), 1.77 (s, 3H), 1.56 (s, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃): $\delta = 202.0$, 172.6, 169.9, 168.3, 152.9, 145.5, 130.9, 113.8, 82.9, 78.2, 60.4, 51.8, 46.0, 44.0, 40.4, 38.5, 36.8, 28.3, 27.4, 22.2 ppm; IR (film) v = 2918, 2850, 1736, 1440, 1360, 1139, 1083, 797 cm⁻¹; MS (ESI): *m/z*: 394 [M+NH₄⁺], 399 [M+Na⁺]; HRMS (ESI) *m/z*: calcd. for C₂₀H₂₄O₇Na [M+Na⁺]: 399.14142, found: 399.14155.


Methyl 2-((*3S*,5*R*,8*S*,8*aR*,10*S*,13*S*)-12-hydroxy-13-methoxy-3-methyl-1,7-dioxo-10-(prop-1en-2-yl)-4,5,7,8,8a,9,10,11-octahydro-1*H*,3*H*-5,8-methanobenzo[g][1,5]dioxecin-3-yl)acetate



(28). Caesium carbonate (131.1 mg, 0.402 mmol) was added to a solution of compound 25 (17.6 mg, 0.0356 mmol) in $CH_2Cl_2/MeOH/H_2O$ (3 mL, 3:2:1) at 0 °C. The resulting mixture was stirred for 10 min at 0°C and for another 60 min at ambient temperature. sat.aq. NH_4Cl (5 mL) was added and

the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over Na₂SO₄, filtered and evaporated, and the residue was purified by flash chromatography on silica (hexanes/EtOAc, 1:1) to afford the title compound as a colorless oil (12.5 mg, 86%). A second fraction consisted of compound **26** (1.6 mg, 11%). $[\alpha]_D^{20} = -79.0$ (c = 0.3, CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 12.01$ (s, 1H), 4.85 (s, 1H), 4.70 (s, 1H), 4.61 (d, J = 6.5 Hz, 1H), 4.07 (t, J = 1.8, 1.8 Hz, 1H), 3.68 (s, 3H), 3.34 (s, 3H), 3.08 (d, J = 15.2 Hz, 1H), 2.85 (d, J = 15.2 Hz, 1H), 2.80 (t, J = 6.0, 6.0 Hz, 1H), 2.66 (d, J = 6.1 Hz, 1H), 2.62–2.55 (m, 1H), 2.54–2.51 (m, 2H), 2.33 (dd, J = 14.9, 6.3 Hz, 1H), 2.31–2.24 (m, 1H), 2.08–2.00 (m, 1H), 1.87 (ddd, J = 13.7, 8.4, 5.8 Hz, 1H), 1.78 (s, 6H) ppm; ¹³C NMR (151 MHz, CDCl₃): $\delta = 176.2$, 174.4, 170.0, 169.8, 146.3, 110.3, 98.3, 93.2, 82.8, 80.9, 56.3, 55.3, 51.7, 45.4, 42.4, 36.5, 36.3, 36.2, 34.0, 26.1, 21.4 ppm; IR (film) v = 2920, 2851, 1770, 1661, 1219, 1096, 803, 728 cm⁻¹; MS (ESI): m/z: 409 [M+H⁺], 431 [M+Na⁺]; HRMS (ESI) m/z: calcd. for C₂₁H₂₈O₈Na [M+Na⁺]: 431.16764, found: 431.16799.

Methyl (*3S*,*5R*,*7aS*,*9S*,*11aR*,*Z*)-5-hydroxy-3-(2-methoxy-2-oxoethyl)-3-methyl-1,11-dioxo-9-(prop-1-en-2-yl)-1,3,4,5,7a,8,9,10,11,11a-decahydrobenzo[c]oxonine-7-carboxylate (26).




 $[\alpha]_{D}^{20} = -30.0 \text{ (c} = 0.16, \text{CHCl}_3); {}^{1}\text{H NMR} (500 \text{ MHz, CDCl}_3): \delta$ = 6.07 (d, J = 10.1 Hz, 1H), 5.69 (td, J = 10.9, 10.8, 3.1 Hz, 1H), 4.94 (s, 1H), 4.66 (s, 1H), 3.80 (s, 3H), 3.69 (s, 3H), 3.53 (d, J = 6.7 Hz, 1H), 3.37-3.29 (m, 1H), 2.94 (dd, J = 15.0, 6.3)

Hz, 1H), 2.90 (s, 1H), 2.76 (d, J = 15.0 Hz, 1H), 2.65 (d, J = 14.2 Hz, 1H), 2.56 (dd, J = 14.5, 10.8 Hz, 1H), 2.50 (d, J = 14.2 Hz, 1H), 2.38 (td, J = 13.6, 13.6, 4.2 Hz, 1H), 2.08 (dd, J = 14.8, 3.1 Hz, 1H), 1.87 (d, J = 14.8 Hz, 1H), 1.74 (s, 3H), 1.68 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃): $\delta = 205.7$, 169.6, 168.4, 166.7, 145.9, 145.0, 131.5, 113.4, 83.0, 67.1, 59.2, 52.1, 51.9, 44.4, 44.0, 39.4, 36.3, 25.8, 24.6, 22.3 ppm; IR (film) v = 3468, 2953, 1709, 1437, 1216, 1163,

1028, 908 cm⁻¹; MS (ESI): *m/z*: 409 [M+H⁺], 426 [M+NH₄⁺], 431 [M+Na⁺]; HRMS (ESI) *m/z*: calcd. for C₂₁H₂₈O₈Na [M+Na⁺]: 431.16764, found: 431.16756.

Sinulariadiolide ((–)-1). A solution of boron tribromide (1 M in CH₂Cl₂, 0.26 mL, 0.26 mmol)



was slowly added to a solution of compound 28 (6.3 mg, temperature for 9 h. The reaction was quenched with

anhydrous Et₂O (0.3 mL) at -78°C. The resulting solution was stirred for 2 min before sat. aq. NaHCO₃ (0.3 mL) was added dropwise to the vigorously stirred mixture. After 15 min, the mixture was allowed to reach ambient temperature. The aqueous phase was extracted with EtOAc (3 x 5 mL), the combined organic layers were washed with brine, dried over Na₂SO₄ and filterred. The filtrate was evaporated and the residue purified by flash chromatography on silica (hexanes/EtOAc, 2:3) to afford the title compound as a white solid (4.4 mg, 72%). $[\alpha]_{D}^{20} = -179$ (c = 0.3, CHCl₃) [ref. 4: $[\alpha]_{D}^{20}$ = +91.1 (c = 0.3, CHCl₃)]; for the ¹H NMR and ¹³C NMR data, see Tables S1 and S2; IR (film) v = 3461, 2951, 1738, 1660, 1372, 1217, 1164, 1027, 756 cm⁻¹; MS (ESI): m/z: 417 [M+Na⁺]; HRMS (ESI) m/z: calcd. for C₂₀H₂₆O₈Na [M+Na⁺]: 417.15199, found: 417.15218.




Table S1. Comparison of the ¹H NMR Data of Sinulariadiolide in CDCl₃; Arbitrary Numbering Scheme as Shown in the Insert


Position	Literature ^[4]		Synthetic sample		Δδ (ppm)
	δ (ppm)	J (Hz)	δ (ppm)	J (Hz)	
3	2.87	(t, J = 5.5)	2.87	(t, J = 6.0)	0
4 a	1.85	(ddd, J = 5.5,	1.85	(ddd, J = 5.7,	0
		8.4,13.2)		8.4,13.6)	
4 b	2.04	(ddd, J = 2.9, 6.7,	2.04	(ddd, J = 2.8, 6.8,	0
		13.2)		13.0)	
5	2.65	m	2.66-2.63	m	
6a	2.26	(dd, <i>J</i> = 6.7, 18.3)	2.29-2.26	m	
6b	2.55	(dd, <i>J</i> = 5.7, 18.3)	2.55	(dd, <i>J</i> = 6.0, 18.6)	0
7	2.56	(d, <i>J</i> = 1.8)	2.56	(d, <i>J</i> = 1.7)	0
8	4.59	brs	4.60	brs	-0.01
9	4.56	(d, J = 6.3)	4.56	(d, J = 6.3)	0
10a	2.28	(dd, J = 6.3, 14.8)	2.28	(dd, <i>J</i> = 6.0, 15.0)	0
10b	2.62	(d, J = 14.8)	2.63	(d, <i>J</i> = 14.8)	-0.01
12a	2.80	(d, <i>J</i> = 15.3)	2.80	(d, <i>J</i> = 15.4)	0
12b	3.09	(d, <i>J</i> = 15.3)	3.11	(d, <i>J</i> = 15.4)	-0.02
15a	4.68	S	4.68	S	
15b	4.83	S	4.84	S	-0.01
16	1.79	S	1.78	S	0.01
18	1.77	S	1.77	S	0
20	3.67	S	3.68	S	-0.01
21	12.0	S	12.0	S	0

Position	Literature ^[4]	Synthetic sample		
	δ (ppm)	δ (ppm)	$\Delta\delta$ (ppm)	
19	176.5	176.3	0.2	
1	174.5	174.5	0	
17	170.1	170.1	0	
13	169.8	169.8	0	
14	146.5	146.4	0.1	
15	110.2	110.2	0	
2	98.3	98.2	0.1	
9	86.0	85.9	0.1	
8	83.8	83.8	0	
11	80.8	80.8	0	
7	58.5	58.4	0.1	
20	51.7	51.7	0	
12	45.3	45.1	0.2	
10	41.8	41.7	0.1	
4	37.0	36.9	0.1	
3	36.3	36.2	0.1	
5	36.2	125.1	0	
6	34.0	33.9	0.1	
18	26.1	26.2	-0.1	
16	21.4	21.5	-0.1	


Table S2. Comparison of the ¹³C NMR Data of Sinulariadiolide in CDCl₃; Numbering Scheme as Shown in the Insert to Table S1

0.2 µL MFA-MA-627-01 Racemat (in 200 µL ACN) 150 mm Chiralcel OZ-3R, 4.6 mm i.D. Acetonitril/Wasser = 60:40 1.0 mL/min, 19.0 MPa, 298 K 220 nm Valve R

:6




¹H NMR Spectrum of 4 (400 MHz, CDCl₃)




¹³C NMR Spectrum of 4 (101 MHz, CDCl₃)







¹H NMR Spectrum of 5 (400 MHz, CDCl₃)




¹³C NMR Spectrum of 5 (101 MHz, CDCl₃)




¹H NMR Spectrum of S1 (400 MHz, CDCl₃)




¹³C NMR Spectrum of S1 (101 MHz, CDCl₃)




¹H NMR Spectrum of 6 (400 MHz, CDCl₃)




¹³C NMR Spectrum of 6 (75 MHz, CDCl₃)




¹H NMR Spectrum of 7 (400 MHz, CDCl₃)




¹³C NMR Spectrum of 7 (101 MHz, CDCl₃)




¹H NMR Spectrum of S2 (600 MHz, CDCl₃)




¹³C NMR Spectrum of S2 (151 MHz, CDCl₃)




COSY Spectrum of S2




HSQC Spectrum of S2







NOESY Spectrum of S2




¹H NMR Spectrum of S3 (400 MHz, CDCl₃)




¹³C NMR Spectrum of S3 (101 MHz, CDCl₃)




¹H NMR Spectrum of 10 (400 MHz, CDCl₃)




¹³C NMR Spectrum of 10 (101 MHz, CDCl₃)




¹H NMR Spectrum of 11 (400 MHz, CDCl₃)




¹³C NMR Spectrum of 11 (101 MHz, CDCl₃)




¹H NMR Spectrum of 15 (400 MHz, CDCl₃)




¹³C NMR Spectrum of 15 (101 MHz, CDCl₃)




¹H NMR Spectrum of 16 (400 MHz, CDCl₃




¹³C NMR Spectrum of 16 (101 MHz, CDCl₃)




¹H NMR Spectrum of 17 (400 MHz, CDCl₃)




¹³C NMR Spectrum of 17 (101 MHz, CDCl₃)




¹H NMR Spectrum of 18 (400 MHz, CDCl₃)




¹³C NMR Spectrum of 18 (101 MHz, CDCl₃)




¹¹⁹Sn NMR Spectrum of 18 (186 MHz, CDCl₃)







---- -58.34


.0









¹H NMR Spectrum of 20 (400 MHz, CDCl₃)



¹³C NMR Spectrum of 20 (151 MHz, CDCl₃)







.0

¹H NMR Spectrum of 30 (400 MHz, CDCl₃) (+ ca. 5-10% of an unidentified impurity, which could not be removed by flash chromatography)


¹³C NMR Spectrum of 30 (151 MHz, CDCl₃) (+ ca. 5-10% of an unidentified impurity, which could not be removed by flash chromatography)







¹H NMR Spectrum of 32 (600 MHz, CDCl₃)

¹³C NMR Spectrum of 32 (151 MHz, CDCl₃)







COSY Spectrum of 32




f1 (ppm)













¹H NMR Spectrum of 25 (400 MHz, CDCl₃)




¹³C NMR Spectrum of 25 (151 MHz, CDCl₃)










¹³C NMR Spectrum of 26 (126 MHz, CDCl₃)












¹H NMR Spectrum of 28 (400 MHz, CDCl₃)




¹³C NMR Spectrum of 28 (151 MHz, CDCl₃)




¹H NMR Spectrum of Sinulariadiolide (1) (600 MHz, CDCl₃)




¹³C NMR Spectrum of Sinulariadiolide (1) (151 MHz, CDCl₃)





Comparison of the ¹H NMR spectrum of synthetic sinulariadiolide (–)-1 (top) and the spectrum of the natural product (bottom)



Comparison of the ¹³C NMR spectrum of synthetic sinulariadiolide (–)-1 (top) and the spectrum of the natural product (bottom)

References

- [1] M. C. Holland, J. B. Metternich, C. Daniliuc, W. B. Schweizer, R. Gilmour, *Chem. Eur. J.* 2015, 21, 10031.
- [2] A. N. Kost, L. N. Khaimov, Y. Dzhurakulov, K. K. Khaidarov, L. D. Lebedeva, A. L. Kotov, *Chem. Heterocycl. Compd.* 1975, 11,1263.
- [3] S. Schaubach, K. Gebauer, F. Ungeheuer, L. Hoffmeister, M. K. Ilg, C. Wirtz, A. Fürstner, *Chem. Eur. J.* 2016, 22, 8494.
- [4] K. Iguchi, K. Kajiyama, H. Miyaoka, Y. Yamada, J. Org. Chem. 1996, 61, 5998.